This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

IMA buys Clinical Trials of America to expand US network

Share this article

IMA Group has acquired research services firm Clinical Trials of America (CTA) to further expand its reach in the US.

IMA Group has acquired research services firm Clinical Trials of America (CTA) to further expand its reach in the US.

The deal – financial terms of which were not disclosed – adds four independent and six embedded locations in Louisiana and North Carolina to IMA’s clinical research site network.

IMA CEO Mark Weinberger said, "the addition of CTA is a natural fit for our organization, expanding our clinical network and adding a large, scalable research business.

He also cited the CRO’s patient access as a factor, explaining “CTA's integrated physician practice research model and focus on recruiting diverse patients ideally fits with IMA Clinical Research's vision and growth trajectory."

The deal comes after a period of substantial expansion for IMA’s clinical trial business according to Weinberger, who said, “our clinical research division has grown more than 300 percent during the past three years.”

Acquisition

IMA said CTA will continue to operate with its existing leadership, investigators and staff remaining in place. CEO Jeb Andrews, who will continue to lead the CRO, also cited the firm’s ability to access patients as key.

"The ability to quickly find the right patients for clinical trial participation, and see those trials through to completion, is critical for researchers today.

"With our track record and experience, our CTA team looks forward to capitalizing on the unique expertise of our two companies to meet the needs of our participants and research sponsors."
The CTA takeover is the seventh IMA Group's Clinical Research division has completed since 2018.

Prior to the CTA, IMA’s most recent acquisition in the clinical space was in March last year when it bought Amici Clinical Research, a clinical trials company with two New Jersey sites in Raritan and Hoboken.

As with the CTA deal, IMA cited network and expertise expansion as the major motivations for the takeover.

Unsplash/paulweaver

Share this article

Sign up for Clinical Insider email updates